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Interleukin-7 (IL-7), a potent thymopoietic cytokine, has the potential to restore impaired immune reconstitution, a major clinical problem limiting the success of allogeneic hematopoietic stem cell transplantation (HSCT). 1 However, its effects on mature T-cell function may have an impact on graft rejection and graft-versus-host disease (GVHD) that would potentially outweigh the intended benefits. The impact of IL-7 in murine HSCT models is controversial, with IL-7 administration both worsening GVHD in some models, 2 and selectively expanding nonalloreactive mature T cells, with no effect on GVHD in others.
3,4 IL-7 is being developed for clinical use in HSCT. However, its effect on the alloreactivity of human T cells remains unknown.
We studied the effects of exogenous IL-7 on T cells in PBMCs from healthy individuals. First, we studied the expression of the IL-7 receptor (IL-7R) in resting cell functional subsets, as defined by the expression of CCR7 and CD45RA 5 ( Figure 1a ). Naı¨ve (CCR7 þ /CD45RA þ ) and central-memory (CCR7 þ /CD45RAÀ) CD8 þ T cells expressed high IL-7R levels (97.2571.91 and 92.05%73.74, respectively), whereas the expression was lower in effector-memory (CCR7À/CD45RAÀ) Figure 1 The effect of IL-7 on the function of alloreactive human T cells in vitro is modulated by downregulation of IL-7R and depends on the timing of its administration. (a) Expression of IL-7R in functional CD4 þ and CD8 þ T-cell subsets from PBMCs from healthy individuals. CD8 þ subsets: naı¨ve CD45RA þ /CCR7 þ , central-memory CD45RAÀ/ CCR7 þ , effector-memory CD45RAÀ/CCR7À, terminally differentiated effectors CD45RA þ /CCR7À. CD4 þ subsets: naı¨ve CD45RA þ / CCR7 þ , memory CD45RAÀ/CCR7 þ , effectors CD45RAÀ/CCR7À (the CD45RA þ /CCR7À subpopulation has not been described in CD4 þ T cells). Data were acquired using four-color fluorescence on a FACSCalibur and analyzed using CellQuest software (BD Systems). The following mouse anti-human monoclonal antibodies were used: anti-CCR7 (2H4, IgM), anti-CD45RA (HI100, IgG2a; MEM56, IgG2b), anti-CD3 (UCHT1, IgG1), anti-CD8 (RPA-T8, IgG1), anti-CD4 (RPA-T4, IgG1), anti-CD127 (M21, IgG1), goat anti-mouse IgM and IgG1, and isotype negative control antibodies (all from BD or Caltag Laboratories). Note that a CD45RA þ /CCR7À terminally differentiated effector subpopulation has not been described in CD4 þ T cells. 5 Next, we studied IL-7R expression upon stimulation using standard MLR. Human alloreactive T cells, defined by the expression of the activation marker CD69 upon MLR allostimulation, downregulated IL-7R expression compared to their CD69-negative nonalloreactive counterparts (21.38711.9 vs 84.7%76.7 at 72 h; Po0.01; Figure 1b) . Median fluorescence intensity of IL-7R expression in nonalloreactive T cells was slightly reduced compared with control resting T cells from the same donors, possibly related to the cytokines being produced in the MLR, in line with evidence showing that IL-2 can induce IL-7R downregulation. 6 Polyclonal CD3/CD28 stimulation of human T cells led to a similar downregulation effect on the expression of IL-7R (data not shown). We went on to assess the effects of exogenous IL-7 on the alloreactivity of allostimulated human T cells using a modified MLR in vitro model of GVHD (Figure 1c ). PBMCs were allostimulated in the absence or presence of exogenous IL-7. On day 8 of the MLR, cells were harvested and stimulated in a second MLR against either the original allostimulus or third-party stimulators. Allostimulated T cells treated with IL-7 from day 1 of the first MLR showed enhanced alloreactivity in the second MLR against the same allostimulus, as expected from the potent effect of IL-7 on mature T cells. Interestingly, allostimulated T cells treated with IL-7 following downregulation of IL-7R on day 3 showed levels of proliferation against the original allostimulus comparable to those in untreated cultures, and higher proliferation in response to third-party stimulators than their counterparts treated with IL-7 on day 1.
Although these results have the limitations of any in vitro studies, they show that human T cells downregulate IL-7R upon allostimulation, which modulates their response to exogenous IL-7 in vitro. This suggests that, in humans, the timing of IL-7 administration in relation to the allostimulus following allogeneic HSCT may determine the functional outcome in terms of alloreactivity, GVHD and response to other third-party antigens. Thus, such timing must be taken into consideration carefully in the forthcoming development and the design of HSCT trials with IL-7 in humans. 
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